Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $688.58 | 9 | 98.2% |
| Education | $12.81 | 1 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $276.47 | 4 | $0 (2024) |
| GlaxoSmithKline, LLC. | $99.46 | 1 | $0 (2024) |
| Penumbra, Inc. | $98.54 | 1 | $0 (2023) |
| Actelion Pharmaceuticals US, Inc. | $81.67 | 2 | $0 (2018) |
| GENZYME CORPORATION | $81.37 | 1 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $63.88 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $280.29 | 3 | AstraZeneca Pharmaceuticals LP ($99.46) |
| 2023 | $198.00 | 2 | AstraZeneca Pharmaceuticals LP ($99.46) |
| 2021 | $40.59 | 1 | AstraZeneca Pharmaceuticals LP ($40.59) |
| 2019 | $100.84 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($63.88) |
| 2018 | $81.67 | 2 | Actelion Pharmaceuticals US, Inc. ($81.67) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $81.37 | General |
| Category: Immunology | ||||||
| 04/18/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $99.46 | General |
| Category: RESPIRATORY | ||||||
| 04/09/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $99.46 | General |
| Category: Respiratory | ||||||
| 11/28/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $99.46 | General |
| Category: Respiratory | ||||||
| 07/11/2023 | Penumbra, Inc. | Indigo System (Device) | Food and Beverage | Cash or cash equivalent | $98.54 | General |
| Category: Peripheral Intervention | ||||||
| 02/23/2021 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $40.59 | General |
| Category: Respiratory | ||||||
| 06/11/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $36.96 | General |
| Category: Respiratory | ||||||
| 05/01/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $63.88 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2018 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $68.86 | General |
| 08/07/2018 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Education | In-kind items and services | $12.81 | General |
| Category: CARDIOVASCULAR DISORDERS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,171 | 1,454 | $568,566 | $101,892 |
| 2022 | 14 | 942 | 1,291 | $502,455 | $99,457 |
| 2021 | 17 | 1,002 | 1,590 | $738,482 | $151,683 |
| 2020 | 18 | 791 | 1,274 | $472,570 | $116,311 |
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 96 | 283 | $321,205 | $47,399 | 14.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 82 | 82 | $43,401 | $10,834 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 112 | 147 | $33,986 | $9,805 | 28.8% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 79 | 93 | $47,523 | $7,833 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 52 | 57 | $17,830 | $5,673 | 31.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 72 | $14,256 | $4,428 | 31.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 34 | 34 | $12,750 | $3,248 | 25.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 20 | $11,160 | $2,701 | 24.2% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 28 | 30 | $6,826 | $2,330 | 34.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 21 | $6,384 | $1,946 | 30.5% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 102 | 105 | $12,222 | $1,731 | 14.2% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 165 | 165 | $17,226 | $1,476 | 8.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 177 | 177 | $13,717 | $1,363 | 9.9% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 168 | 168 | $10,080 | $1,126 | 11.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 108 | 279 | $302,085 | $48,377 | 16.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 55 | 189 | $35,453 | $10,613 | 29.9% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 93 | 109 | $53,161 | $9,533 | 17.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 81 | 100 | $21,888 | $7,463 | 34.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 38 | 41 | $12,280 | $4,640 | 37.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 34 | 38 | $13,510 | $4,062 | 30.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 25 | 25 | $12,437 | $3,432 | 27.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 22 | $11,736 | $3,403 | 29.0% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2022 | 34 | 35 | $8,763 | $2,686 | 30.6% |
| 94618 | Test for exercise-induced lung stress | Facility | 2022 | 81 | 82 | $9,055 | $1,420 | 15.7% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 115 | 115 | $6,073 | $1,055 | 17.4% |
About Dr. Michael Delacruz, M.D
Dr. Michael Delacruz, M.D is a Internal Medicine healthcare provider based in Ephrata, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2008. The National Provider Identifier (NPI) number assigned to this provider is 1629232087.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Delacruz, M.D has received a total of $701.39 in payments from pharmaceutical and medical device companies, with $280.29 received in 2024. These payments were reported across 10 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($688.58).
As a Medicare-enrolled provider, Delacruz has provided services to 3,906 Medicare beneficiaries, totaling 5,609 services with total Medicare billing of $469,342. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Internal Medicine
- Location Ephrata, PA
- Active Since 07/15/2008
- Last Updated 08/31/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1629232087
Products in Payments
- AIRSUPRA (Drug) $99.46
- AREXVY (Drug) $99.46
- TEZSPIRE (Biological) $99.46
- Indigo System (Device) $98.54
- DUPIXENT (Biological) $81.37
- OFEV (Drug) $63.88
- FASENRA (Biological) $40.59
- FASENRA (Drug) $36.96
- UPTRAVI (Drug) $12.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Ephrata
Arun Agrawal, Md, MD
Internal Medicine — Payments: $8,661
Agnieszka Mochon, Md, MD
Internal Medicine — Payments: $3,350
Prasad Krishnakurup, M.d, M.D
Internal Medicine — Payments: $1,945
Darshan Lal, Md, MD
Internal Medicine — Payments: $886.72
Dr. Eugene Camerino, D.o, D.O
Internal Medicine — Payments: $518.77
Andrew Ambort, Do, DO
Internal Medicine — Payments: $272.99